Cantor Fitzgerald Lowers Artiva Biotherapeutics (NASDAQ:ARTV) Price Target to $20.00

Artiva Biotherapeutics (NASDAQ:ARTV) had its price target cut by Cantor Fitzgerald from $23.00 to $20.00 in a research note published on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other brokerages have also weighed in on ARTV. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday. Wedbush restated an “outperform” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday. Finally, HC Wainwright initiated coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They set a “buy” rating and a $20.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Artiva Biotherapeutics has an average rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Stock Up 2.0 %

Artiva Biotherapeutics stock opened at $3.99 on Tuesday. The company has a 50 day moving average price of $4.91 and a 200-day moving average price of $9.37. Artiva Biotherapeutics has a fifty-two week low of $3.37 and a fifty-two week high of $17.31.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in Artiva Biotherapeutics in the third quarter worth about $152,234,000. Franklin Resources Inc. purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $7,435,000. Geode Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $4,774,000. Samsara BioCapital LLC purchased a new stake in Artiva Biotherapeutics during the third quarter valued at approximately $4,506,000. Finally, Wellington Management Group LLP acquired a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $2,912,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.